NCT02182206已完成1 期
A Phase I Open Label Dose Escalation Study of Continuous Once-daily or Twice Daily Oral Treatment With BIBF 1120 in Patients With Advanced Solid Tumours
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 主要终点
- Maximum Tolerated Dose (MTD) of BIBF 1120
研究概览
简要总结
Maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamic parameters (Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI))
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients with confirmed diagnosis of advanced, non resectable and/or metastatic solid tumours, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who were not amenable to established forms of treatment
- •Measurable tumour deposits by one or more techniques (X-ray), Computed Tomography (CT), Magnetic Resonance Imaging (MRI))
- •At least one tumour lesion considered suitable for DCE-MRI as determined by discussion with centre radiologist. This lesion must not have been previously irradiated
- •Age 18 years or older
- •Life expectancy of at least three months
- •Written informed consent given consistent with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines
- •Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1
- •Patients completely recovered from any therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies
排除标准
- •Surgical procedures within four weeks of initiating treatment with the study drug, active ulcers, or injuries with incomplete wound healing
- •Active infectious disease
- •Uncontrolled, severe hypertension (diastolic BP (Blood Pressure) >100 mmHg, Systolic BP>180 mmHg)
- •Gastrointestinal disorders that might have interfered with the resorption of the study drug
- •Serious illness or concomitant non-oncological disease considered by the investigator to have been incompatible with the protocol
- •Brain metastases requiring therapy
- •Absolute neutrophil count less than 1500/mm3
- •Platelet count less than 100 000/mm3
- •Bilirubin greater than 1.5 mg/dl (>26 μmol/L, System International (SI) unit equivalent)
- •Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than three times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
- •Serum creatinine greater than 1.5 mg/dl (>132μmol/L, SI unit equivalent)
- •Women and men who were sexually active and unwilling to use a medically acceptable method of contraception
- •Pregnancy or breastfeeding
- •Treatment with other investigational drugs; chemotherapy or hormone therapy (excluding Lutenizing Hormone Releasing Hormone (LHRH) agonists or bisphosphonates provided the lesion for MR (magnetic resonance) imaging did not arise from bone) or participation in another clinical study within the past four weeks before start of therapy or concomitantly with this study
- •Patients unable to comply with the protocol
- •Active alcohol or drug abuse
- •History of autoimmune disease
- •History of allergy to gadolinium or other intravenous (IV) contrast agent, indwelling medical devices or any other condition that would preclude MR scanning
- •Patients requiring the ongoing use of dexamethasone, anti-histamines, anti-hypertensives or medications for the control of cardiac failure such as diuretics, where there was likely to be a need for alteration of dose during the study period. Dose adjustment of such medications may have independently altered vascular permeability or blood flow
研究组 & 干预措施
BIBF 1120
Experimental
干预措施: BIBF 1120 (Drug)
结局指标
主要结局
Maximum Tolerated Dose (MTD) of BIBF 1120
时间窗: Up to 7 months
Incidence and intensity of Adverse Events according to common toxicity criteria (CTC) associated with increasing doses of BIBF 1120
时间窗: Up to 7 months
次要结局
- Transfer constant (Ktrans)(Screening, day 2, 28 and 56)
- Extravascular-extracellular leakage volume (ve)(Screening, day 2, 28 and 56)
- Area under the gadolinium concentration time curve [0-60 seconds] (AUC[Gd])(Screening, day 2, 28 and 56)
- Relative blood volume (rBV)(Screening, day 2, 28 and 56)
- Mean transit time (MTT)(Screening, day 2, 28 and 56)
- Relative blood flow (rBF)(Screening, day 2, 28 and 56)
- Volume of tumour showing contrast uptake(Screening, day 2, 28 and 56)
- Volume of tumour showing no contrast uptake(Screening, day 2, 28 and 56)
- Restricted diffusion(Screening, day 2, 28 and 56)
- Vessel size index(Screening, day 2, 28 and 56)
- Change in Eastern Cooperative Oncology Group (ECOG) performance score(Baseline, up to 7 months)
- Objective tumour responses according to the response evaluation criteria in solid tumour (RECIST)(Baseline, up to 7 months)
- Area under the plasma concentration-time curve following the first dose of uniform intervals τ over the time interval from zero to 24 hours (AUCτ,1)(up to 24 hours after the first dose on day 1)
- Area under the plasma concentration-time curve over the time interval from zero to the time of the last quantifiable drug concentration (AUC0-tz)(up to 24 hours after the first dose on day 1)
- Area under the plasma concentration-time curve over the time interval from zero extrapolated to infinity (AUC0-∞)(up to 24 hours after the first dose on day 1)
- Maximum measured plasma concentration following the first dose of uniform intervals τ (Cmax,1)(up to 24 hours after the first dose on day 1)
- Time from dosing to the maximum plasma concentration following the first dose of uniform intervals τ (tmax,1)(up to 24 hours after the first dose on day 1)
- Terminal half-life (t1/2)(up to 24 hours after the first dose on day 1)
- Mean residence time (MRTpo)(up to 24 hours after the first dose on day 1)
- Apparent clearance (CL/F)(up to 24 hours after the first dose on day 1)
- Apparent volume of distribution during the terminal phase (Vz/F)(up to 24 hours after the first dose on day 1)
- Area under the plasma concentration-time curve over the dosing interval τ (24 h) at steady state (AUCτ,ss)(up to 24 hours after drug administration on day 27)
- Predose plasma concentration at steady state immediately before dosing (Cpre,ss)(up to 24 hours after drug administration on day 27)
- Maximum plasma concentration at steady state over the dosing interval τ (Cmax,ss)(up to 24 hours after drug administration on day 27)
- Time from dosing to the maximum plasma concentration at steady state over the dosing interval τ (tmax,ss)(up to 24 hours after drug administration on day 27)
- Terminal half-life at steady state (t1/2,ss)(up to 24 hours after drug administration on day 27)
- Apparent clearance at steady state (CL/F,ss)(up to 24 hours after drug administration on day 27)
- Mean residence time at steady state (MRTpo,ss),(up to 24 hours after drug administration on day 27)
- Predose concentration of the 15th dose over the dosing interval τ (Cpre,15)(pre-dose on day 15)
- Time from last dosing to the minimum plasma concentration at steady state over the dosing interval τ (tmin,ss)(up to 24 hours after drug administration on day 27)
- Apparent volume of distribution during the terminal phase at steady state (Vz/F,ss)(up to 24 hours after drug administration on day 27)
- Accumulation ratio (RA)(up to 24 hours after drug administration on day 27)
- Minimum measured plasma concentration following the first dose of uniform intervals τ (Cmin,1)(up to 24 hours after the first dose on day 1)
- Time from first dosing to the minimum plasma concentration over the dosing interval τ (tmin,1)(up to 24 hours after the first dose on day 1)
- Minimum measured plasma concentration at steady state over the dosing interval τ (Cmin,ss)(up to 24 hours after drug administration on day 27)
研究者
相似试验
已完成
1 期
An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT02182141Boehringer Ingelheim17
已完成
1 期
A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid TumoursTumorsNCT02182128Boehringer Ingelheim24
已完成
1 期
To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid TumoursMalignant Solid TumourNCT01951846Boehringer Ingelheim61
已完成
1 期
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)Carcinoma, Non-Small-Cell LungNCT01684111Aktion Bronchialkarzinom e.V.7
终止
1 期
Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)Ovarian NeoplasmsNCT01329549Boehringer Ingelheim2